Some have relabeled it as Pentadecapeptide Aringate or PDA (shifting the acetate to an arginate) and therefore are prescribing it for subcutaneous administration this way, whilst the confusion about its position has brought about a lively oral capsule market for BPC in what appears to generally be a gray region https://denisb443zri3.luwebs.com/profile